The study will follow patients who receive the new Mitris Resilia valve developed by Edwards Lifesciences, according to an April 17 press release.
The valve has already been approved by the FDA, and Hoag has performed more than a dozen mitral valve replacements in the last eight months.
Hoag’s study investigators include surgeons Anthony Caffarelli, MD, Asad Shah, MD, and Timothy Lee, MD.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
